Med-IQ (@MedIQCME) header
Med-IQ (@MedIQCME) profile picture

Med-IQ

@MedIQCME

We empower people at every level of the healthcare delivery system with the knowledge needed to continuously improve provider performance and patient outcomes.

 Baltimore, MD
med-iq.com
Joined September 2009
  • Tweets7.4K
  • Following371
  • Followers1.3K
1.8KMedia
Photo by Med-IQ (@MedIQCME)Photo by Med-IQ (@MedIQCME)Photo by Med-IQ (@MedIQCME)Photo by Med-IQ (@MedIQCME)Photo by Med-IQ (@MedIQCME)Photo by Med-IQ (@MedIQCME)Photo by Med-IQ (@MedIQCME)Photo by Med-IQ (@MedIQCME)Photo by Med-IQ (@MedIQCME)Photo by Med-IQ (@MedIQCME)
Thoracoabdominal aortic aneurysms can remain asymptomatic until serious complications occur. Understanding when to refer, when to intervene, and how to individualize repair decisions is critical to optimizing patient outcomes. Learn how to match the repair strategy to the patient in this complimentary CME activity: clinical.med-iq.com/activity…
Complimentary CME Contemporary Management of Thoracoabdominal Aortic Aneurysm: Matching the Repair to the Patient Explore surgical referral thresholds, patient-specific repair selection, spinal cord protection strategies, and lifelong surveillance post repair.

ALT Complimentary CME Contemporary Management of Thoracoabdominal Aortic Aneurysm: Matching the Repair to the Patient Explore surgical referral thresholds, patient-specific repair selection, spinal cord protection strategies, and lifelong surveillance post repair.

17
Thank you to Ahmad Masri, MD, MS, for his live updates on emerging and potentially practice-changing clinical data in the treatment of ATTR-CM treatment from the 2026 AHA Scientific Sessions this past weekend! Check out this thread for highlights.
Image from Med-IQ (@MedIQCME)
1
3
3
304
more replies
Favorable myocardial structural changes in response to eplontersen vs placebo in the CARDIO-TTRansform trial #CardioTwitter #AHA2026 #MedIQScientificSessions26
Image from Med-IQ (@MedIQCME)
Image from Med-IQ (@MedIQCME)
Image from Med-IQ (@MedIQCME)
1
7
Eplontersen echo study showing attenuation of progression of various echo metrics in monotherapy ahajournals.org/doi/10.1161/… #CardioTwitter #AHA2026 #MedIQScientificSessions26
Image from Med-IQ (@MedIQCME)
Image from Med-IQ (@MedIQCME)
Image from Med-IQ (@MedIQCME)
Image from Med-IQ (@MedIQCME)
10
Early transplant referral can help delay, or even avoid, dialysis in patients with advanced CKD. Explore key strategies in this complimentary CME: clinical.med-iq.com/activity…
Complimentary CME Advanced Chronic Kidney Disease: How Do We Prolong Life and Avoid Dialysis? Identifying candidates sooner allows for living donor evaluation and may help delay or avoid dialysis.

ALT Complimentary CME Advanced Chronic Kidney Disease: How Do We Prolong Life and Avoid Dialysis? Identifying candidates sooner allows for living donor evaluation and may help delay or avoid dialysis.

24
How are emerging surgical innovations changing the future of lung transplantation? Gain insights into the latest developments in robotic surgery and ex vivo lung perfusion and their potential to improve transplant care and outcomes. Access CME → clinical.med-iq.com/activity…
Surgical Advancements in Lung Transplant Key advancements in patient assessment and surgical techniques that are reshaping lung transplant outcomes Jacob A. Klapper, MD, FACS Thoracic Surgeon Duke Health

ALT Surgical Advancements in Lung Transplant Key advancements in patient assessment and surgical techniques that are reshaping lung transplant outcomes Jacob A. Klapper, MD, FACS Thoracic Surgeon Duke Health

26
Thank you to Elliot Tapper, MD, FAASLD, for his live updates on the latest HBV research from The Liver Meeting 2026 this past weekend! Check out this thread for highlights.
Image from Med-IQ (@MedIQCME)
1
1
72
more replies
Repurposing a prevention vaccine as therapy? Phase 1: 2 doses of TLR9-adjuvanted HbSag (HEPLISAV-B_ in 10 NUC-treated pts with HBV were safe, HBsAg fell modestly (0.1–0.5 log) in 8, and anti-HBs rose in 2. #MedIQTLM26 #HBV
Image from Med-IQ (@MedIQCME)
1
11
Treat HBV with normal ALT (<40 U/L)? PROMOTE randomized 193 such pts to Tenofovir amibufenamide (TMF) vs no treatment: 82% on TMF had HBV DNA <20 IU/mL at Wk144, and 9 untreated controls progressed to meet treatment criteria. #MedIQTLM26 #HBV
21
Load more